New York, April 09, 2019 (GLOBE NEWSWIRE) -- Univest Securities client INmune Bio, Inc. (INmune Bio) (NASDAQ: INMB), a clinical stage immunology biotech company developing therapies in patients’ innate immune system for both cancer and neurological disease, is scheduled to ring The Nasdaq Stock Market Closing Bell at the Nasdaq MarketSite in Times Square at 4:00 PM Eastern time, Tuesday, April 9, 2019. A live webcast of The Nasdaq Stock Market Closing Bell ceremony will be available at: https://new.livestream.com/nasdaq/live.
INmune Bio’s common stock commenced trading on the NASDAQ Capital Market (“NASDAQ”) on February 4th, 2019. Univest Securities, LLC acted as the lead book running manager for its IPO.
“INmune Bio has recently been awarded a grant to receive $1,000,000 from the Alzheimer's Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease, ” Edric Yi Guo, Head of Investment Banking of Univest Securities stated. He continued, “We are excited and honored to ring the closing bell at the Nasdaq in celebration of our client’s successful listing. As INmune Bio has positioned themselves as an immunological company targeting both oncological and neurological diseases, we very much look forward to seeing INmune Bio’s further delivery of value for its shareholders in the future. I would like to express appreciation to the company’s management, our team and investors for their trust, support and extreme hard work.”
About Univest Securities, LLC.
Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services to its institutional and retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. It strives to provide clients with value-add service and focuses on building long-term relationship with its clients. For more information, please visit: www.univest.us
About INmune Bio Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact:
Univest Securities, LLC
Edric Guo, COO
yguo@univest.us
375 Park Avenue, 1502
New York, NY 10152
INmune Bio, Inc.
David Moss, CFO
dmoss@inmunebio.com
1224 Prospect Str. Suite 150
La Jolla, CA 92037